<
 
 
 
 
>
hide
You are viewing a Web site, archived on 03:43:32 Oct 19, 2004. It is now a Federal record managed by the National Archives and Records Administration.
External links, forms, and search boxes may not function within this collection.
[Skip navigation] FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
Powered by Google
New from CDER
 October 15. FDA today issued a Public Health Advisory announcing a multi-pronged strategy to warn the public about the increased risk of suicidal thoughts and behavior ("suicidality") in children and adolescents being treated with antidepressant medications. More Information.
 October 14. FDA approves four first-time generics for Carboplatin for initial and secondary treatment of advanced ovarian cancer. The reference listed drug is Paraplatin.
 October 13. FDA and Centocor notify healthcare professionals of revisions to the prescribing information for Remicade, indicated for the treatment of rheumatoid arthritis and Crohn's disease. In controlled studies of all TNFα-blocking agents, including Remicade, more cases of lymphoma have been observed among patients receiving the agents than among control group patients. MedWatch Safety Info.
 October 8. FDA approves first-time generic Gabapentin for adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults with epilepsy. The reference listed drug is Neurontin.
 October 8. Biogen Idec and Genentech notify healthcare professionals of revisions to the prescribing section of the Rituxan (rituximab) label due to reports of Hepatitis B virus (HBV) reactivation with fulminant hepatitis, hepatic failure, and death in some patients with hematologic malignancies. MedWatch Safety Info.
 October 4. FDA and King Pharmaceuticals notify healthcare professionals of revisions to the Levoxyl labeling, describing reports of choking, gagging, tablets stuck in throat and dysphagia while taking Levoxyl.  MedWatch Safety Info.
Previous News Items
 


Recently Added Pages

Vioxx Information
21st Century Initiative on the Regulation of Pharmaceutical Manufacturing.
 
  


Main FDA number: 1-888-INFO-FDA (1-888-463-6332)
Drug Information Number: 301-827-4570  (8:00 am - 4:30 pm Eastern Time)

 

Page Last Updated: October 15, 2004


  Healthfinder.gov
MEDLINEplus

FirstGov

horizonal rule